Axsome Therapeutics, Inc. (AXSM) fair value analysis
Nasdaq · Updated 2026-09-07
Axsome Therapeutics, Inc. is a biopharmaceutical company that develops and commercializes novel therapies for central nervous system disorders, including depression, migraine, and other neurological conditions. The company operates in the United States and conducts research and development activities to bring new treatment options to market.
Valuation status
Awaiting full valuationAXSM does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under our standards — we require at least six validated trailing price-to-earnings windows before publishing one. TickrTrends re-evaluates every covered stock weekly; a verdict publishes automatically once enough validated history accumulates.
- Last price
- $211.04
- Sector
- Healthcare
- 12-month range
- $118.57–$240.66
Derived indicators
Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.
- Quality grade
- D
- Leverage
- High
- RSI zone
- Neutral
- 50/200-day trend
- Mixed
- 52-week position
- The top quarter of its range
What our data shows for AXSM
- Shares are trading in the upper third of their 12-month price range of $118.57–$240.66.
- The 14-day relative strength index sits at a neutral 47.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for AXSM
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
How Forward Fair Value works
TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.
Recent AXSM news
TickrTrends' derived news-sentiment signal for AXSM is currently mixed, computed from recent coverage.
- Axsome Therapeutics (AXSM) Gains Buy Rating Amid Smoking Cessation Trial, But Valuation Remains Elevated (gurufocus.com, 2026-08-31)
TickrTrends take: Axsome Therapeutics received a buy rating following progress in its smoking cessation trial, though analysts have flagged elevated valuation concerns for the Healthcare sector company. TickrTrends is currently awaiting full valuation data on AXSM, meaning comprehensive metrics needed to assess whether current pricing aligns with fundamentals remain incomplete. For valuation-focused investors, the key question is whether the company's pipeline advancement will justify its current market valuation once full financial analysis becomes available. - Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation (manilatimes.net, 2026-08-31)
TickrTrends take: Axsome Therapeutics is advancing AXS-05 into late-stage clinical testing for smoking cessation, a condition affecting millions of smokers globally and representing a substantial market opportunity if regulatory approval is achieved. The Phase 3 SUMMIT trial outcome will be a critical data point for determining the commercial viability of this indication, directly influencing the company's valuation once results become available. Investors focused on valuation should monitor trial enrollment rates and interim data readouts, as clinical success or failure in this program could materially impact Axsome's revenue projections and pipeline value. - Amgen vs. Axsome Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? (finance.yahoo.com, 2026-08-29)
TickrTrends take: Axsome Therapeutics operates in a competitive Healthcare sector landscape where direct comparisons to larger players like Amgen are common among investors seeking value opportunities. TickrTrends' current assessment for AXSM remains in an awaiting full valuation status, indicating that comprehensive pricing analysis is still being developed for this name. Investors focused on valuation metrics should monitor for completion of this analysis, as comparative positioning within the Healthcare sector will likely become clearer once full valuation data is finalized.
What people are saying
Follow the AXSM conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is AXSM stock undervalued?
AXSM does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under TickrTrends' standards; it is re-evaluated every week.
What is AXSM's TickrTrends verdict?
AXSM is currently marked 'Awaiting full valuation' - a verdict publishes automatically once at least six validated trailing P/E windows accumulate.
Is AXSM overbought or oversold?
AXSM's 14-day RSI is in neutral territory - neither overbought nor oversold.